BASKING RIDGE, NJ, December 16, 2025 /24-7PressRelease/ -- Dr. Frank L. Douglas PhD, MD, has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Dr. Douglas, a distinguished figure in the fields of medicine and pharmaceuticals, has made significant contributions to both academia and industry. His career is marked by a series of influential roles, including his current one: since 2024, he has served as a board member of the Diaspora Human Genomics Institute, an organization dedicated to addressing the underrepresentation of Black individuals in genomic research, a cause Dr. Douglas passionately supports. Through collaboration with pharmaceutical companies like Regeneron and Novo Nordisk the Institute advances diversity in genomic studies, ensuring broader inclusion in medical research. Dr. Douglas is also adjunct professor in the Meharry Medical College's School of Graduate Studies.

In addition to his role at the institute, Dr. Douglas has served since 2020 as the chief executive officer of Safe Haven Dialogues, LLC. Here, he leads workshops and hosts the "Antifragility Reframe Podcast" focusing on helping individuals and organizations navigate conflict and bias. His methodology encourages participants to identify broader issues that affect larger groups, fostering collective efforts and alliances. This approach stems from his personal experiences with discrimination throughout his career.

Dr. Douglas also holds the position of scientific advisor and chairman of the scientific advisory board at EOM Pharmaceuticals. His expertise in pharmaceutical innovation is further demonstrated through his role as vice president of real-world clinical research and outcomes at the Center for Medicine in the Public Interest. Additionally, he has been a technical and board advisor for XaTek since 2018. These roles highlight his commitment to advancing medical research and patient care.

Dr. Douglas's illustrious career in pharmaceuticals includes serving as senior vice president and head of research for Ciba Geigy, which later became Novartis, for three years. He then became executive vice president, board member, and global head of research and development and regulatory affairs for Marion Merrill Dow before its acquisition by Hoechst. His career culminated as an executive vice president and board member of Aventis, now Sanofi, before retiring in 2004. In academia, he was Professor of the Practice at MIT and the Harvard-MIT Division of Health, Science and Technology and was the founder of the MIT Center for Biomedical Innovation. Following his time at MIT, he became University Professor at the University of Akron and Founding CEO of the Austen Bioinnovation Institute in Akron, which was a collaboration among the three Akron Hospitals, the University of Akron, and the Northeast Ohio Medical University.

Dr. Douglas's academic journey began with a Bachelor of Science in chemistry from Lehigh University in 1966, followed by a Ph.D. in physical chemistry and a Doctor of Medicine from Cornell University. He also holds certifications in diversity and inclusion from Cornell University and investing in human skills in the age of AI from LinkedIn.

Throughout his career, Dr. Douglas has been recognized with numerous awards, including the Rockstar of Science award from Geoffrey Beeene Foundation and GQ Magazine in 2010, as well as being named Global Pharmaceutical R&D Director and Chief Scientific Officer of the Year in 2001 and 2004. He is also an accomplished author with publications such as "Defining Moments of a Free Man from a Black Stream" and "Until You Walk in My Shoes: A Reframe Methodology to Overcome Systemic Discrimination"

Dr. Douglas attributes much of his success to his upbringing in British Guiana (now Guyana), where he had to seek education abroad due to limited local opportunities. His perseverance was further tested during his graduate studies at Cornell University when he learned that resilience was more critical for success than intelligence alone. This lesson has guided him throughout his career.

Dr. Douglas's current work is deeply rooted in reframing — a strategy that has contributed significantly to his success as an innovator in the pharmaceutical industry. He aims to share this approach widely, particularly within social contexts where challenges are complex, viewing difficulties as opportunities for new solutions. His mission is to encourage others to see these moments as valuable opportunities for rethinking and resolving deeper systemic problems.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #